BEST CURRENT EVIDENCE ON CHEST PHYSIOTHERAPY IN NON-VENTILATED
... yielded 10,016 study titles. Studies were chosen from the population of studies using pre-set inclusion and exclusion ...
... yielded 10,016 study titles. Studies were chosen from the population of studies using pre-set inclusion and exclusion ...
CHMP assessment report Note Zydelig
... of 4 per 100,000 persons per year. The median age of diagnosis in the EU is 72 years and only 10% of patients are less than 55 years old. The current WHO classification system recognizes and groups CLL and small lymphocytic lymphoma (SLL) as the same biological entity, with CLL clinically manifestin ...
... of 4 per 100,000 persons per year. The median age of diagnosis in the EU is 72 years and only 10% of patients are less than 55 years old. The current WHO classification system recognizes and groups CLL and small lymphocytic lymphoma (SLL) as the same biological entity, with CLL clinically manifestin ...
Annual Report - Breast Cancer Institute of Australia
... During the reporting period, 39 new publications were added to the ANZBCTG peer-reviewed publication portfolio. As new trials begin, other trials reach their accrual targets, progress into follow-up phase and data is prepared for analysis and publication. The global accrual targets for the SOFT and ...
... During the reporting period, 39 new publications were added to the ANZBCTG peer-reviewed publication portfolio. As new trials begin, other trials reach their accrual targets, progress into follow-up phase and data is prepared for analysis and publication. The global accrual targets for the SOFT and ...
evista - Eli Lilly Canada
... Heart (RUTH) study was 2.70 and 3.88 events per 1,000 person-years for placebo and raloxifene 60mg/day, respectively. Other venous thromboembolic events could also occur. A less serious event, superficial thrombophlebitis, also has been reported more frequently with EVISTA. The greatest risk for dee ...
... Heart (RUTH) study was 2.70 and 3.88 events per 1,000 person-years for placebo and raloxifene 60mg/day, respectively. Other venous thromboembolic events could also occur. A less serious event, superficial thrombophlebitis, also has been reported more frequently with EVISTA. The greatest risk for dee ...
Headaches: Evidence Update October 2014
... 8 times a month for 6 months or more were recruited from 77 sites in the USA. In the 12-week run-in stage of the study, all participants were instructed to treat 1 moderateto-severe migraine with placebo. Those who reported pain at 2 hours after treatment were then randomly assigned to placebo or to ...
... 8 times a month for 6 months or more were recruited from 77 sites in the USA. In the 12-week run-in stage of the study, all participants were instructed to treat 1 moderateto-severe migraine with placebo. Those who reported pain at 2 hours after treatment were then randomly assigned to placebo or to ...
AusPAR: Armodafinil - Therapeutic Goods Administration
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. ...
... The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. ...
Implications of Recent Clinical Trials for the National Cholesterol
... option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C ⬍100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholestero ...
... option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C ⬍100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholestero ...
Tybost - Gilead Sciences, Inc.
... interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. (5.3, 7, 12.3). ------------------------DOSAGE AND ADMINISTRATION --------------------- TYBOST must be coadministered with ataza ...
... interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. (5.3, 7, 12.3). ------------------------DOSAGE AND ADMINISTRATION --------------------- TYBOST must be coadministered with ataza ...
valdoxan
... Gender, smoking and age: No significant difference in exposure was shown between the young and the elderly as well as between males and females. Although not clinically relevant: - a 3.7-fold decrease in mean exposure was observed in volunteers without depression who were heavy smokers (≥15 cigarett ...
... Gender, smoking and age: No significant difference in exposure was shown between the young and the elderly as well as between males and females. Although not clinically relevant: - a 3.7-fold decrease in mean exposure was observed in volunteers without depression who were heavy smokers (≥15 cigarett ...
AusPAR: Pomalidomide - Therapeutic Goods Administration
... Pomalidomide has not been considered previously by the Advisory Committee on Prescription Medicines (ACPM). Pomalidomide was granted orphan drug status by the TGA on 17 October 2012: For the treatment of MM in patients who have failed two or more prior therapies. The proposed indication is more rest ...
... Pomalidomide has not been considered previously by the Advisory Committee on Prescription Medicines (ACPM). Pomalidomide was granted orphan drug status by the TGA on 17 October 2012: For the treatment of MM in patients who have failed two or more prior therapies. The proposed indication is more rest ...
Evaluation of the Guideline Definition Language
... Efforts to create a clinical decision support system (CDSS) which would contribute in the improvement of safety and efficiency in health care began as early as 1960 [1]. Since then many definitions have been introduced in order to describe what clinical decision support (CDS) is, but in a simplistic ...
... Efforts to create a clinical decision support system (CDSS) which would contribute in the improvement of safety and efficiency in health care began as early as 1960 [1]. Since then many definitions have been introduced in order to describe what clinical decision support (CDS) is, but in a simplistic ...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
... > Sub-bullet was removed: “Start 24-72 h after completion of chemotherapy. Administration of growth factor on the same day as chemotherapy is not recommended.” > Sub-bullets 2 through 4 were added: 7 The majority of trials administered pegfilgrastim the day after chemotherapy (category 1). 7 Adminis ...
... > Sub-bullet was removed: “Start 24-72 h after completion of chemotherapy. Administration of growth factor on the same day as chemotherapy is not recommended.” > Sub-bullets 2 through 4 were added: 7 The majority of trials administered pegfilgrastim the day after chemotherapy (category 1). 7 Adminis ...
SOPHIRIS BIO INC.
... potential efficacy will be evidenced by histological and MRI changes, indicating tumor control at six months following treatment. The clinical trial is being conducted at a single center, the University College London, which is well known for the focal treatment of prostate cancer in the United King ...
... potential efficacy will be evidenced by histological and MRI changes, indicating tumor control at six months following treatment. The clinical trial is being conducted at a single center, the University College London, which is well known for the focal treatment of prostate cancer in the United King ...
Pediatric allergic rhinitis: Factors affecting treatment
... limited in all patients with allergic rhinitis.12 The efficacy and safety of some second-generation antihistamines in children have been assessed in a number of well-designed clinical trials. Four of these agents are currently available for use in children in the U.S.: fexofenadine is indicated for u ...
... limited in all patients with allergic rhinitis.12 The efficacy and safety of some second-generation antihistamines in children have been assessed in a number of well-designed clinical trials. Four of these agents are currently available for use in children in the U.S.: fexofenadine is indicated for u ...
Front-Line therapy in CLL: Assessment of Ibrutinib
... Complete the relevant SAE or SUSAR CRF for all SAEs and SUSARs occurring in the trial and fax to the CTRU within 24 hours of becoming aware of the event: Fax: 0113 343 1487 A receipt will be sent for all received SAEs. If a receipt is not received within two working days contact the Data Management ...
... Complete the relevant SAE or SUSAR CRF for all SAEs and SUSARs occurring in the trial and fax to the CTRU within 24 hours of becoming aware of the event: Fax: 0113 343 1487 A receipt will be sent for all received SAEs. If a receipt is not received within two working days contact the Data Management ...
Assessment report - Voncento - HUMAN COAGULATION FACTOR
... Prevention and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Voncento 250 IU/600 IU is indicated in adults and in adolescents from 12-18 years. Haemophilia A (congenital FVIII deficiency): Prophylaxis ...
... Prevention and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Voncento 250 IU/600 IU is indicated in adults and in adolescents from 12-18 years. Haemophilia A (congenital FVIII deficiency): Prophylaxis ...
SYNAGIS® (palivizumab) CODING RESOURCE
... respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart dis ...
... respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart dis ...
List of amendments in this update
... 7. Seek independent advice (i) The Guidelines are intended to aid Permitted Users in the management of their patients but do not provide explanations as to the conditions or treatments outlined. There may be clinical or other reasons for using different therapy. In all cases, users should understand ...
... 7. Seek independent advice (i) The Guidelines are intended to aid Permitted Users in the management of their patients but do not provide explanations as to the conditions or treatments outlined. There may be clinical or other reasons for using different therapy. In all cases, users should understand ...
Product Monograph
... 211 and 202 premature infants or children with chronic lung disease received solution for injection and lyophilized SYNAGIS®, respectively. In two additional studies (MI-CP110 and MI-CP124), SYNAGIS® solution for injection was used as an active control (3918 pediatric subjects) to evaluate an invest ...
... 211 and 202 premature infants or children with chronic lung disease received solution for injection and lyophilized SYNAGIS®, respectively. In two additional studies (MI-CP110 and MI-CP124), SYNAGIS® solution for injection was used as an active control (3918 pediatric subjects) to evaluate an invest ...
Fact sheets
... placebo on sleep maintenance and sleep initiation, as well as next-day residual effect and next-day ...
... placebo on sleep maintenance and sleep initiation, as well as next-day residual effect and next-day ...
Inhaled dry powder mannitol in cystic
... Subjects A total of 389 subjects with confirmed CF were enrolled from sites in Australia, Ireland, New Zealand and the UK. Eligible subjects were aged o6 yrs and had a baseline forced expiratory volume in 1 s (FEV1) of o30 and ,90% predicted. Exclusion criteria included failing a mannitol tolerance ...
... Subjects A total of 389 subjects with confirmed CF were enrolled from sites in Australia, Ireland, New Zealand and the UK. Eligible subjects were aged o6 yrs and had a baseline forced expiratory volume in 1 s (FEV1) of o30 and ,90% predicted. Exclusion criteria included failing a mannitol tolerance ...
this document - Association of the British Pharmaceutical
... supply innovative modern therapies in the future, it has to rely on the commercial success of medicines already in use, and the existence of a receptive regulatory and market environment . Britain has traditionally been at the forefront of international medicines research - only the USA has discover ...
... supply innovative modern therapies in the future, it has to rely on the commercial success of medicines already in use, and the existence of a receptive regulatory and market environment . Britain has traditionally been at the forefront of international medicines research - only the USA has discover ...
ABC Clinical Guide 2003 - American Botanical Council
... Vogel, 1970). Indigenous Americans prepared an aqueous infusion of the berries to treat stomachache and dysentery (Duke, 1985). They also used the fruit as a diuretic and sexual tonic (Duke, 1985). Since the mid-1990s, saw palmetto has been one of the ten top-selling herbs in the U.S. (Blumenthal et ...
... Vogel, 1970). Indigenous Americans prepared an aqueous infusion of the berries to treat stomachache and dysentery (Duke, 1985). They also used the fruit as a diuretic and sexual tonic (Duke, 1985). Since the mid-1990s, saw palmetto has been one of the ten top-selling herbs in the U.S. (Blumenthal et ...
PROCALCITONIN: Contributing to IMPROVED CLINICAL …
... of SIRS, Sepsis, Severe Sepsis and Septic shock as defined by SCCM/ACCP Discuss the role of biomarkers, clinical presentation, and other laboratory tests used in the evaluation of patients with suspected Sepsis Recognize how procalcitonin, other biomarkers, and clinical exam can assist in early reco ...
... of SIRS, Sepsis, Severe Sepsis and Septic shock as defined by SCCM/ACCP Discuss the role of biomarkers, clinical presentation, and other laboratory tests used in the evaluation of patients with suspected Sepsis Recognize how procalcitonin, other biomarkers, and clinical exam can assist in early reco ...
Berinert - CSL Behring
... infections, and by processes demonstrated to inactivate and/or remove certain viruses during manufacturing [see Description (11) and Patient Counseling Information (17)]. Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectio ...
... infections, and by processes demonstrated to inactivate and/or remove certain viruses during manufacturing [see Description (11) and Patient Counseling Information (17)]. Despite these measures, such products may still potentially transmit disease. There is also the possibility that unknown infectio ...